ENSG00000104517 |
|
esophageal adenocarcinoma |
sequence_alteration |
9.132% (40/438) |
1 entry |
ENSG00000104517 |
|
esophageal adenocarcinoma |
frameshift_variant |
9.132% (40/438) |
1 entry |
ENSG00000104517 |
|
Mantle cell lymphoma |
stop_gained |
12.95% (25/193) |
2 entries |
ENSG00000104517 |
|
colorectal adenocarcinoma |
sequence_alteration |
10.11% (126/1246) |
2 entries |
ENSG00000104517 |
|
esophageal adenocarcinoma |
missense_variant |
9.132% (40/438) |
1 entry |
ENSG00000104517 |
|
breast ductal adenocarcinoma |
sequence_alteration |
13.97% (102/730) |
1 entry |
ENSG00000104517 |
|
melanoma |
missense_variant |
13.86% (14/101) |
2 entries |
ENSG00000104517 |
|
Mantle cell lymphoma |
frameshift_variant |
12.95% (25/193) |
2 entries |
ENSG00000104517 |
|
colorectal adenocarcinoma |
stop_gained |
10.11% (126/1246) |
2 entries |
ENSG00000104517 |
|
colorectal adenocarcinoma |
missense_variant |
10.11% (126/1246) |
6 entries |
ENSG00000104517 |
|
HER2 Positive Breast Carcinoma |
missense_variant |
12.58% (20/159) |
2 entries |
ENSG00000104517 |
|
colorectal adenocarcinoma |
frameshift_variant |
10.11% (126/1246) |
3 entries |
ENSG00000104517 |
|
Mantle cell lymphoma |
missense_variant |
12.95% (25/193) |
3 entries |
ENSG00000104517 |
|
melanoma |
frameshift_variant |
13.86% (14/101) |
1 entry |
ENSG00000104517 |
|
Mantle cell lymphoma |
sequence_alteration |
12.95% (25/193) |
2 entries |
ENSG00000104517 |
|
breast ductal adenocarcinoma |
missense_variant |
13.97% (102/730) |
1 entry |
ENSG00000104517 |
|
prostate adenocarcinoma |
missense_variant |
4.883% (71/1454) |
1 entry |
ENSG00000104517 |
|
head and neck squamous cell carcinoma |
sequence_alteration |
2.011% (15/746) |
1 entry |
ENSG00000104517 |
|
cecum adenocarcinoma |
stop_gained |
11.36% (15/132) |
1 entry |
ENSG00000104517 |
|
gastric adenocarcinoma |
frameshift_variant |
4.15% (32/771) |
2 entries |
ENSG00000104517 |
|
head and neck squamous cell carcinoma |
missense_variant |
2.011% (15/746) |
2 entries |
ENSG00000104517 |
|
Dysplasia in Ulcerative Colitis |
missense_variant |
25.0% (2/8) |
1 entry |
ENSG00000104517 |
|
prostate carcinoma |
missense_variant |
3.099% (15/484) |
1 entry |
ENSG00000104517 |
|
prostate adenocarcinoma |
stop_gained |
4.883% (71/1454) |
1 entry |
ENSG00000104517 |
|
female breast carcinoma |
missense_variant |
3.069% (12/391) |
3 entries |
ENSG00000104517 |
|
pancreatic ductal adenocarcinoma |
missense_variant |
5.163% (65/1259) |
2 entries |
ENSG00000104517 |
|
Merkel cell skin cancer |
missense_variant |
10.0% (3/30) |
1 entry |
ENSG00000104517 |
|
ovarian serous adenocarcinoma |
missense_variant |
1.189% (8/673) |
1 entry |
ENSG00000104517 |
|
Cervical Small Cell Carcinoma |
missense_variant |
50.0% (3/6) |
1 entry |
ENSG00000104517 |
|
bladder transitional cell carcinoma |
missense_variant |
2.92% (4/137) |
2 entries |
ENSG00000104517 |
|
non-small cell lung carcinoma |
missense_variant |
8.257% (9/109) |
3 entries |
ENSG00000104517 |
|
bile duct adenocarcinoma |
missense_variant |
1.058% (2/189) |
1 entry |
ENSG00000104517 |
|
esophageal squamous cell carcinoma |
frameshift_variant |
3.259% (22/675) |
2 entries |
ENSG00000104517 |
|
gastric adenocarcinoma |
sequence_alteration |
4.15% (32/771) |
1 entry |
ENSG00000104517 |
|
ovarian serous adenocarcinoma |
sequence_alteration |
1.189% (8/673) |
2 entries |
ENSG00000104517 |
|
esophageal squamous cell carcinoma |
stop_gained |
3.259% (22/675) |
3 entries |
ENSG00000104517 |
|
hepatocellular carcinoma |
missense_variant |
2.323% (22/947) |
2 entries |
ENSG00000104517 |
|
nasopharyngeal squamous cell carcinoma |
missense_variant |
1.198% (2/167) |
1 entry |
ENSG00000104517 |
|
lung adenocarcinoma |
stop_gained |
3.273% (40/1222) |
2 entries |
ENSG00000104517 |
|
clear cell renal carcinoma |
missense_variant |
1.379% (19/1378) |
2 entries |
ENSG00000104517 |
|
basal cell carcinoma |
missense_variant |
10.34% (6/58) |
1 entry |
ENSG00000104517 |
|
colon adenocarcinoma |
sequence_alteration |
5.867% (45/767) |
3 entries |
ENSG00000104517 |
|
large cell lung carcinoma |
missense_variant |
11.11% (2/18) |
1 entry |
ENSG00000104517 |
|
alveolar rhabdomyosarcoma |
missense_variant |
3.39% (2/59) |
2 entries |
ENSG00000104517 |
|
basal cell carcinoma |
sequence_alteration |
10.34% (6/58) |
1 entry |
ENSG00000104517 |
|
colon adenocarcinoma |
stop_gained |
5.867% (45/767) |
4 entries |
ENSG00000104517 |
|
brain glioblastoma |
missense_variant |
0.324% (3/926) |
1 entry |
ENSG00000104517 |
|
clear cell renal carcinoma |
sequence_alteration |
1.379% (19/1378) |
1 entry |
ENSG00000104517 |
|
skin melanoma |
missense_variant |
4.033% (39/967) |
6 entries |
ENSG00000104517 |
|
metaplastic breast carcinoma |
missense_variant |
7.843% (4/51) |
1 entry |
ENSG00000104517 |
|
chronic lymphocytic leukemia |
missense_variant |
1.014% (9/888) |
2 entries |
ENSG00000104517 |
|
skin melanoma |
sequence_alteration |
4.033% (39/967) |
2 entries |
ENSG00000104517 |
|
prostate carcinoma |
sequence_alteration |
3.099% (15/484) |
1 entry |
ENSG00000104517 |
|
adenosquamous lung carcinoma |
missense_variant |
27.27% (3/11) |
1 entry |
ENSG00000104517 |
|
gastric adenocarcinoma |
missense_variant |
4.15% (32/771) |
4 entries |
ENSG00000104517 |
|
colon adenocarcinoma |
frameshift_variant |
5.867% (45/767) |
3 entries |
ENSG00000104517 |
|
colon adenocarcinoma |
missense_variant |
5.867% (45/767) |
5 entries |
ENSG00000104517 |
|
breast carcinoma |
missense_variant |
1.843% (26/1411) |
2 entries |
ENSG00000104517 |
|
cecum adenocarcinoma |
missense_variant |
11.36% (15/132) |
1 entry |
ENSG00000104517 |
|
esophageal squamous cell carcinoma |
missense_variant |
3.259% (22/675) |
5 entries |
ENSG00000104517 |
|
cecum adenocarcinoma |
frameshift_variant |
11.36% (15/132) |
2 entries |
ENSG00000104517 |
|
papillary renal cell carcinoma |
missense_variant |
0.597% (2/335) |
1 entry |
ENSG00000104517 |
|
gastric intestinal type adenocarcinoma |
frameshift_variant |
11.76% (10/85) |
2 entries |
ENSG00000104517 |
|
small cell lung carcinoma |
missense_variant |
1.548% (5/323) |
3 entries |
ENSG00000104517 |
|
bladder carcinoma |
missense_variant |
6.306% (35/555) |
1 entry |
ENSG00000104517 |
|
prostate adenocarcinoma |
sequence_alteration |
4.883% (71/1454) |
2 entries |
ENSG00000104517 |
|
oral squamous cell carcinoma |
missense_variant |
2.927% (6/205) |
4 entries |
ENSG00000104517 |
|
gastric intestinal type adenocarcinoma |
missense_variant |
11.76% (10/85) |
2 entries |
ENSG00000104517 |
|
ovarian carcinoma |
missense_variant |
40.0% (4/10) |
1 entry |
ENSG00000104517 |
|
Ampulla of Vater Carcinoma |
missense_variant |
2.353% (2/85) |
1 entry |
ENSG00000104517 |
|
clear cell renal carcinoma |
frameshift_variant |
1.379% (19/1378) |
1 entry |
ENSG00000104517 |
|
lung adenocarcinoma |
missense_variant |
3.273% (40/1222) |
8 entries |
ENSG00000104517 |
|
squamous cell lung carcinoma |
missense_variant |
2.4% (21/875) |
4 entries |
ENSG00000104517 |
|
rectal adenocarcinoma |
missense_variant |
1.762% (4/227) |
2 entries |
ENSG00000104517 |
|
ulcerative colitis |
missense_variant |
11.11% (1/9) |
1 entry |
ENSG00000104517 |
|
osteosarcoma |
frameshift_variant |
1.724% (2/116) |
1 entry |
ENSG00000104517 |
|
oral squamous cell carcinoma |
frameshift_variant |
2.927% (6/205) |
1 entry |
ENSG00000104517 |
|
skin carcinoma |
missense_variant |
4.808% (5/104) |
1 entry |
ENSG00000104517 |
|
female breast carcinoma |
stop_gained |
3.069% (12/391) |
1 entry |
ENSG00000104517 |
|
diffuse gastric adenocarcinoma |
missense_variant |
1.266% (1/79) |
1 entry |
ENSG00000104517 |
|
Pancreatic Acinar Cell Carcinoma |
sequence_alteration |
15.0% (3/20) |
1 entry |
ENSG00000104517 |
|
endometrial stromal sarcoma |
missense_variant |
8.333% (1/12) |
1 entry |
ENSG00000104517 |
|
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
sequence_alteration |
16.67% (1/6) |
1 entry |
ENSG00000104517 |
|
bladder transitional cell carcinoma |
sequence_alteration |
2.92% (4/137) |
1 entry |
ENSG00000104517 |
|
skin melanoma |
frameshift_variant |
4.033% (39/967) |
1 entry |
ENSG00000104517 |
|
gastric intestinal type adenocarcinoma |
sequence_alteration |
11.76% (10/85) |
1 entry |
ENSG00000104517 |
|
Ocular Sebaceous Carcinoma |
stop_gained |
4.348% (1/23) |
1 entry |
ENSG00000104517 |
|
Brain Stem Glioblastoma |
frameshift_variant |
3.571% (2/56) |
1 entry |
ENSG00000104517 |
|
bronchoalveolar adenocarcinoma |
missense_variant |
4.545% (1/22) |
1 entry |
ENSG00000104517 |
|
endometrial carcinoma |
stop_gained |
4.348% (1/23) |
1 entry |
ENSG00000104517 |
|
Pancreatic Acinar Cell Carcinoma |
frameshift_variant |
15.0% (3/20) |
1 entry |
ENSG00000104517 |
|
basal cell carcinoma |
stop_gained |
10.34% (6/58) |
1 entry |
ENSG00000104517 |
|
neoplasm |
missense_variant |
7.143% (2/28) |
1 entry |
ENSG00000104517 |
|
ovarian mucinous adenocarcinoma |
missense_variant |
7.692% (1/13) |
1 entry |
ENSG00000104517 |
|
endometrial carcinoma |
missense_variant |
4.348% (1/23) |
1 entry |
ENSG00000104517 |
|
adenosquamous lung carcinoma |
sequence_alteration |
27.27% (3/11) |
1 entry |
ENSG00000104517 |
|
medullary thyroid gland carcinoma |
sequence_alteration |
5.263% (1/19) |
1 entry |
ENSG00000104517 |
|
small cell lung carcinoma |
stop_gained |
1.548% (5/323) |
1 entry |
ENSG00000104517 |
|
female breast carcinoma |
frameshift_variant |
3.069% (12/391) |
1 entry |
ENSG00000104517 |
|
Merkel cell skin cancer |
sequence_alteration |
10.0% (3/30) |
1 entry |
ENSG00000104517 |
|
large cell lung carcinoma |
stop_gained |
11.11% (2/18) |
1 entry |
ENSG00000104517 |
|
lung adenocarcinoma |
sequence_alteration |
3.273% (40/1222) |
1 entry |
ENSG00000104517 |
|
lung adenocarcinoma |
conservative_inframe_deletion |
3.273% (40/1222) |
1 entry |
ENSG00000104517 |
|
Testicular Non-Seminomatous Germ Cell Tumor |
missense_variant |
33.33% (1/3) |
1 entry |
ENSG00000104517 |
|
acute lymphoblastic leukemia |
missense_variant |
0.3115% (1/321) |
1 entry |
ENSG00000104517 |
|
head and neck squamous cell carcinoma |
frameshift_variant |
2.011% (15/746) |
1 entry |
ENSG00000104517 |
|
osteosarcoma |
sequence_alteration |
1.724% (2/116) |
1 entry |
ENSG00000104517 |
|
nodular melanoma |
missense_variant |
50.0% (1/2) |
1 entry |
ENSG00000104517 |
|
ovarian neoplasm |
sequence_alteration |
1.724% (1/58) |
1 entry |
ENSG00000104517 |
|
Endometrial Clear Cell Adenocarcinoma |
missense_variant |
8.333% (1/12) |
1 entry |
ENSG00000104517 |
|
rectal adenocarcinoma |
frameshift_variant |
1.762% (4/227) |
1 entry |
ENSG00000104517 |
|
gastric intestinal type adenocarcinoma |
stop_gained |
11.76% (10/85) |
1 entry |
ENSG00000104517 |
|
embryonal rhabdomyosarcoma |
missense_variant |
1.316% (1/76) |
1 entry |
ENSG00000104517 |
|
non-small cell lung carcinoma |
stop_gained |
8.257% (9/109) |
1 entry |
ENSG00000104517 |
|
ependymoma |
sequence_alteration |
2.174% (1/46) |
1 entry |
ENSG00000104517 |
|
Brain Stem Glioblastoma |
sequence_alteration |
3.571% (2/56) |
1 entry |
ENSG00000104517 |
|
Pancreatic Acinar Cell Carcinoma |
missense_variant |
15.0% (3/20) |
1 entry |
ENSG00000104517 |
|
squamous cell lung carcinoma |
stop_gained |
2.4% (21/875) |
1 entry |
ENSG00000104517 |
|
squamous cell lung carcinoma |
sequence_alteration |
2.4% (21/875) |
1 entry |